Hackler R, Arndt T, Helwig-Rolig A, Kropf J, Steinmetz A, Schaefer J R
Zentrum für Innere Medizin, Abteilung Kardiologie, Baldingerstrasse, Philipps-Universität, D-35033 Marburg, Germany.
Clin Chem. 2000 Apr;46(4):483-92.
The introduction of a new set of reagents for the determination of carbohydrate-deficient transferrin (CDT) as a marker of chronic alcohol abuse requires an independent evaluation of the analytic specificity of the test. This information is needed for correct interpretation and classification of test results.
Isoelectric focusing on the PhastSystem(TM) followed by immunofixation, silver staining, and densitometry was used to validate the initial transferrin isoform fractionation step on anion-exchange microcolumns involved in the ChronAlcoI.D. assay.
The in vitro transferrin iron load was complete and stable. The CDT and non-CDT transferrin fractionation on anion-exchange microcolumns was reliable and reproducible (CV < or = 10%). Except for quantitatively unimportant traces of trisialo-Fe(2)-transferrin (<5% of total CDT), only asialo-, mono-, and disialo-Fe(2)-transferrin were detected in the microcolumn eluates (n = 170). There was a loss of proportionally similar amounts of asialo-Fe(2)-transferrin (during column rinsing) and disialo-Fe(2)-transferrin (on the anion exchanger). Thus, the peak height ratios for disialo- and asialo-Fe(2)-transferrin did not change from >1 (serum) to <1 (eluates) as described for the CDTect assays. The transferrin patterns in the ChronAlcoI.D. eluates were representative of those in serum. Transferrin D variants with isoelectric points close to that of trisialo-Fe(2)-transferrin C1 did not cause overdetermination of CDT by the ChronAlcoI.D. test.
The initial CDT and non-CDT fractionation step involved in determination of CDT by the ChronAlcoI.D. assay is efficient for eliminating non-CDT transferrins from serum before quantification of CDT in the final turbidimetric immunoassay. We recommend IEF for validation of other (commercial) CDT analysis methods and of odd CDT results.
引入一套用于测定缺糖转铁蛋白(CDT)作为慢性酒精滥用标志物的新试剂,需要对该检测的分析特异性进行独立评估。正确解释和分类检测结果需要此信息。
使用PhastSystem™等电聚焦,随后进行免疫固定、银染和光密度测定,以验证ChronAlcoI.D.检测中涉及的阴离子交换微柱上初始转铁蛋白异构体分级步骤。
体外转铁蛋白铁负荷完整且稳定。阴离子交换微柱上CDT和非CDT转铁蛋白分级可靠且可重复(CV≤10%)。除了定量上不重要的痕量三唾液酸-Fe(2)-转铁蛋白(<总CDT的5%)外,微柱洗脱液(n = 170)中仅检测到去唾液酸、单唾液酸和双唾液酸-Fe(2)-转铁蛋白。去唾液酸-Fe(2)-转铁蛋白(在柱冲洗过程中)和双唾液酸-Fe(2)-转铁蛋白(在阴离子交换剂上)损失的比例相似。因此,双唾液酸和去唾液酸-Fe(2)-转铁蛋白的峰高比不像CDTect检测那样从>1(血清)变为<1(洗脱液)。ChronAlcoI.D.洗脱液中的转铁蛋白模式代表血清中的模式。等电点接近三唾液酸-Fe(2)-转铁蛋白C1的转铁蛋白D变体不会导致ChronAlcoI.D.检测对CDT的过度测定。
ChronAlcoI.D.检测中测定CDT所涉及的初始CDT和非CDT分级步骤,在最终比浊免疫测定中对CDT进行定量之前,能有效地从血清中去除非CDT转铁蛋白。我们建议使用等电聚焦来验证其他(商业)CDT分析方法和异常CDT结果。